We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed at $750.12 in the latest trading session, marking a +1.56% move from the prior day. This change outpaced the S&P 500's 0.62% gain on the day. At the same time, the Dow added 0.5%, and the tech-heavy Nasdaq lost 5.66%.
Coming into today, shares of the biopharmaceutical company had lost 1.46% in the past month. In that same time, the Medical sector lost 2.88%, while the S&P 500 gained 3.44%.
Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $10.22, up 4.61% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.07 billion, up 7.42% from the prior-year quarter.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $41.09 per share and revenue of $12.78 billion. These results would represent year-over-year changes of -8.65% and +4.96%, respectively.
Investors should also note any recent changes to analyst estimates for Regeneron. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Regeneron is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Regeneron's current valuation metrics, including its Forward P/E ratio of 17.98. Its industry sports an average Forward P/E of 19.92, so we one might conclude that Regeneron is trading at a discount comparatively.
Also, we should mention that REGN has a PEG ratio of 2. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
Regeneron (REGN - Free Report) closed at $750.12 in the latest trading session, marking a +1.56% move from the prior day. This change outpaced the S&P 500's 0.62% gain on the day. At the same time, the Dow added 0.5%, and the tech-heavy Nasdaq lost 5.66%.
Coming into today, shares of the biopharmaceutical company had lost 1.46% in the past month. In that same time, the Medical sector lost 2.88%, while the S&P 500 gained 3.44%.
Regeneron will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $10.22, up 4.61% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.07 billion, up 7.42% from the prior-year quarter.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $41.09 per share and revenue of $12.78 billion. These results would represent year-over-year changes of -8.65% and +4.96%, respectively.
Investors should also note any recent changes to analyst estimates for Regeneron. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Regeneron is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Regeneron's current valuation metrics, including its Forward P/E ratio of 17.98. Its industry sports an average Forward P/E of 19.92, so we one might conclude that Regeneron is trading at a discount comparatively.
Also, we should mention that REGN has a PEG ratio of 2. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.83 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.